breast-cancer-summit-2017-scientifictracks-abstracts

6 / 12

Page 29
Notes:
conferenceseries.com
Volume 2, Issue 2 (Suppl) Breast Can Curr Res
ISSN: 2572-4118 BCCR, an open access journal Breast Cancer Summit 2017
May 08-10, 2017
May 08-10, 2017 Singapore
4th World Congress on
Breast Cancer
How personalized medicine and personalized monitoring using non-invasive method could improve
treatment for breast cancer
Fu Zhuo-Han Marc and Jean-François Laes
OncoDNA, Belgium
Statement of the Problem: Breast cancer (BC) is the most common cancer amongst women in Europe, with one out of eight
developing this disease during her lifetime. In the last few decades, surgical excision followed by adjuvant radiotherapy, sentinel lymph
node dissection, and adjuvant systemic therapy in the form of chemotherapy, hormonal therapy and Trastuzumab have improved
the quality of life and long‐term survival of women diagnosed with early disease. However, BC remains the leading cause of female
cancer-related death worldwide. Thanks to the NGS and other tests (like IHCs, methylation), it is now possible to perform a profiling
of the tumor to identify either treatments that might be associated with some clinical benefit or resistance to approved treatment.
Methodology: Biopsies of women affected by different breast cancer type have been analysed by sequencing and some specific tests
(methylation, IHCs).
Findings: Overall, the NGS provided the oncologist with no use in 50% to 90% of the cases whereas the IHCs/specific tests increase
this number by a factor 2 with the caviar of the combination of both. These results were prospectively compared to the decision of the
oncologists in an automated way. 23.2% of the patients passed away before the oncologist’s decision. Among the 76.8% remaining,
59.7% followed our recommendations, 27.5% didn’t and 3.1%went against. Only in 6.6% of the cases, the decision was taken according
to the NGS only, and 95.4% remaining concerned chemotherapies only. And in 100% of the cases, the treatment chosen was either a
drug approved for the cancer type analysed or approved for another cancer type. None of the drugs in development in clinical trial
was chosen and only 1% went into a clinical trial.
Conclusion & Significance: This study demonstrated how simple strategies based on the NGS only have a limited impact on the
oncologist’s final decision confronted to the reality where only chemotherapies are available in their countries and clinical trials are
either not recruiting or really difficult to get into.
Biography
Fu Zhuo-Han Marc : After a Master in biomedical engineering at UCL. He is currently Business Developer at OncoDNA. It is an exciting challenge to combine
scientific and sales knowledge to further develop OncoDNA’s activities in South East Asian Regions.
Fu Zhuo-Han Marc et al., Breast Can Curr Res 2017, 2:2(Suppl)